Cox-2 Inhibitors: Today and Tomorrow
- 1 April 2002
- journal article
- review article
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 323 (4) , 181-189
- https://doi.org/10.1097/00000441-200204000-00003
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma☆Journal of Allergy and Clinical Immunology, 2001
- The economic implications of cyclooxygenase-2–specific inhibitorsThe American Journal of Medicine, 2001
- Extent, mode, and dose dependence of anticancer effectsThe American Journal of Medicine, 2001
- Tolerability profiles of rofecoxib (Vioxx®) and Arthrotec®: A comparison of six weeks treatment in patients with osteoarthritisScandinavian Journal of Rheumatology, 2001
- Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in SwitzerlandPharmacoEconomics, 2001
- Evaluation of intravenous parecoxib for the relief of acute post-surgical painExpert Opinion on Investigational Drugs, 2000
- RofecoxibExpert Opinion on Pharmacotherapy, 2000
- Celecoxib-Induced Acute Pancreatitis and Hepatitis: A Case ReportArchives of internal medicine (1960), 2000
- Potential utility of COX-2 inhibitors in chemoprevention and chemotherapyExpert Opinion on Investigational Drugs, 1999
- Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritisKidney International, 1995